Please select your page

Knight Therapeutics Inc. Appoints New CFO

MONTREAL, CANADA – (February 28, 2014) – Knight Therapeutics Inc. (TSX-V: GUD) (“Knight”) announced today that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans. Mr. Kadanoff holds a B. Eng. with Distinction in Chemical Engineering and a Minor in Management from McGill University, and an M.B.A. with Distinction from INSEAD.


About Knight Therapeutics Inc.:

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics’ shares are expected to begin trading on the TSX-V on March 3, 2014 under the symbol GUD. For more information about Knight Therapeutics, please visit the Company's web site at www.gud-knight.com or at www.sedar.com.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the Company’s final application for listing on the TSX Venture and can be found on SEDAR at www.sedar.com, which investors should consult for additional information. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact Jonathan Ross Goodman at 514-484-4483.

Buy now

You can now buy this awesome Joomla Theme directly on Themeforest for a really low price for this awesome and stunning Joomla product!

Nulla vitae elit libero, a pharetra augue. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porta sem malesuada magna mollis euismod. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nulla vitae elit libero, a pharetra augue.

BUY NOW ON THEMEFOREST

×

Login

Please login using your credentials recived by email when you register.

  or   Create an account

Forgot your password? |  Forgot your username?

×

Register now


I'm a small Introtext for the Register Module, I can be set in the Backend of the Joomla WS-Register Module.



  or   Login
×